Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

GlaxoSmithKline's Patent on Retrovir Expires; Generic Versions of AZT Expected to Be Available Soon

September 20, 2005

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

The patent on azidothymidine, or AZT -- the main ingredient in GlaxoSmithKline's antiretroviral drug Retrovir -- expired on Saturday, paving the way for lower-cost generic versions to be made available for millions of HIV-positive people in developing countries and thousands in the U.S., the Raleigh News & Observer reports (Vollmer [1], Raleigh News & Observer, 9/18). In the U.S., AZT currently is available only as Retrovir; however, drug companies in China, India and some African countries in July began preparing to make generic AZT. Generic versions could cost about $105 for an annual supply, roughly 20% less than the least expensive AZT currently available worldwide (Vollmer [2], Raleigh News & Observer, 9/18). When FDA first approved Retrovir in 1987, it cost up to $10,000 per person annually, but by 1989 the price was lowered to about $2,200 for an annual supply (Raleigh News & Observer [1], 9/18). GSK does not expect its revenue to be affected by the patent expiration because it will not affect the price of Combivir and Trizivir, its newest drugs containing AZT, which in 2004 brought in combined sales of $1.6 billion (Raleigh News & Observer [2], 9/18).

Back to other news for September 20, 2005


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2005 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News on AZT (Zidovudine, Retrovir)

Tools
 

Advertisement